Provided by Tiger Trade Technology Pte. Ltd.

Senti Biosciences, Inc.

2.13
-0.0900-4.05%
Post-market: 2.200.0700+3.29%19:47 EST
Volume:131.48K
Turnover:281.38K
Market Cap:55.72M
PE:-0.71
High:2.25
Open:2.24
Low:2.06
Close:2.22
52wk High:7.10
52wk Low:1.26
Shares:26.16M
Float Shares:9.58M
Volume Ratio:1.53
T/O Rate:1.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9839
EPS(LYR):-12.0350
ROE:-394.62%
ROA:-67.77%
PB:6.86
PE(LYR):-0.18

Loading ...

Senti Biosciences Initiated at Outperform by Leerink Partners

Dow Jones
·
Nov 21

Buy Rating for Senti Biosciences: Innovative Gene Circuit Platform Shows Promise in AML Treatment

TIPRANKS
·
Nov 21

Senti Biosciences Q3 Net Income USD -18.126 Million

Reuters
·
Nov 20

Cell therapy developer Senti Biosciences' Q3 net loss narrows

Reuters
·
Nov 14

BRIEF-Senti Biosciences Q3 Net Income USD -18.126 Million

Reuters
·
Nov 14

Senti Biosciences Q3 EPS USD -0.69

THOMSON REUTERS
·
Nov 14

Press Release: Senti Bio Reports Third Quarter 2025 Financial Results and Confirms Next Clinical Data Readout for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) at the American Society of Hematology Annual Meeting in December

Dow Jones
·
Nov 14

BUZZ-U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart

Reuters
·
Oct 15

BUZZ-H.C. Wainwright initiates Senti Biosciences with 'Buy' on cell therapy hopes

Reuters
·
Oct 14

Senti Biosciences Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Oct 14

HC Wainwright Initiates Coverage on Senti Biosciences With Buy Rating, $12 Price Target

MT Newswires Live
·
Oct 14

Senti Biosciences, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating

THOMSON REUTERS
·
Oct 14

Senti Bio Participates in Virtual Investor “What This Means” Segment Discussing the Phase 2 Dose and Schedule Selection for Senti-202 in Its Clinical Trial for Acute Myeloid Leukemia

THOMSON REUTERS
·
Aug 12

Senti Biosciences Q2 EPS $(0.56) Beats $(0.90) Estimate

Benzinga
·
Aug 07

Senti Biosciences Reports Q2 2025 Financial Results: Cash Holdings Decrease to $21.6M, R&D Expenses Rise by $0.8M

Reuters
·
Aug 07

BRIEF-Senti Biosciences Q2 Net Income USD -14.733 Million

Reuters
·
Aug 07

Senti Biosciences Q2 Operating Income USD -16.798 Million

THOMSON REUTERS
·
Aug 07

Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 Senti-202 Study in Acute Myeloid Leukemia (Aml) Expected Q4 2025

THOMSON REUTERS
·
Aug 07

BRIEF-Senti Bio Determines Recommended Phase 2 Dose (RP2D) In Phase 1 Study Of Senti-202

Reuters
·
Aug 05

Senti Biosciences Inc - Senti-202 Well-Tolerated, No Dose Limiting Toxicities

THOMSON REUTERS
·
Aug 05